Real world data and evidence
At Parexel, we develop strategies and implement approaches to deliver the right evidence across all stages of the product development and post-approval lifecycle. We align with our customers’ clinical and commercial goals to generate evidence by real-world research that:
- Supports approval and post-marketing regulatory requirements
- Drives the differentiation of value against standard of care, comparable products on the market and new entrants
- Enables patients to continue access to medicines in a real-world setting
Our solutions
- Clinical interventional: Phase IIIb, Pragmatic trials, Post authorization clinical trial commitment, External control arm
- Extension studies: Rollover and long-term follow up
- Post-trial access: Rollover, Early access program, Managed access program, Compassionate use
- Licence/label expansion
- Non-drug interventional
- Prospective studies: Post-marketing commitments, PASS/PAES, Natural history, survey, COA, surveillance
- Retrospective studies: Chart review, Natural history, External control, PASS, Burden of disease, HEOR
- Registries: Product, Disease, Pregnancy
- Protocol design & development/ Medical writing/publication
- Epidemiology lifecycle strategy
- Analysis & reporting
- Integrated evidence planning
- Regulatory engagement
- COA sciences: Design, Development, Implementation
- Data insights: Feasibility, Design Optimization, Diversity
- Secondary data studies: Database landscaping & feasibility, Data use agreements, Data partnerships, Analytics
- Data engineering: Common data model, RWD/RWE evidence engine
- Sensors: TA-aligned solutions, E2E delivery models, Digital endpoints
Trust Parexel’s Real World Research team to deliver
- Integrated evidence planning: Parexel’s Real World Research teams are committed to helping you meet the expectations of regulators, payers, physicians and patients and give you the competitive edge – through an integrated evidence strategy.
- The right data sources: We develop strategies, identify and apply the right data sources that generate Real World Evidence throughout the product lifecycle to help differentiate your products, beginning at the earliest stages of development.
- Multi-disciplinary experts to align functions: Experts working at each step of the development process look ahead to align functions, anticipate needs, and address challenges proactively across the product lifecycle, including end-to-end evidence generation and communication solutions for Medical Affairs
Our Experts
Mike D’Ambrosio
Senior Vice President and Global Head, Real World Research
Ian Hall
Senior Director, Real-World Evidence and Market Access Solutions
Declan Keogh
Vice President, Process and Quality, Scientific Data Organization
Becky Thompson
Senior Director, Real-World Evidence and Market Access Solutions
Vaneet Nayar
Senior Director, Real-World Evidence (RWE)
Matthew Gordon
Vice President, Real-World Evidence Strategy
David Brown
VP, Epidemiology
Our Experts
Mike D’Ambrosio
Senior Vice President and Global Head, Real World Research
Ian Hall
Senior Director, Real-World Evidence and Market Access Solutions
Declan Keogh
Vice President, Process and Quality, Scientific Data Organization
Becky Thompson
Senior Director, Real-World Evidence and Market Access Solutions
Vaneet Nayar
Senior Director, Real-World Evidence (RWE)
Matthew Gordon
Vice President, Real-World Evidence Strategy
related insights
Webinar
Leveraging post-marketing regulatory requirements to drive commercial value
Oct 16, 2024
Blog
Transforming evidence generation: How predictive AI can optimize clinical development
Sep 3, 2024
Whitepaper
Combining data tokenization and real-world patient insights to bridge the gap for a more diverse and complete dataset
Apr 2, 2024
Blog
Deriving meaningful insights from real-world data for diverse Alzheimer’s research studies
Mar 19, 2024
Blog
Removing barriers through pragmatic clinical trials
Oct 12, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
Guide for Real-World Evidence
May 21, 2021
Article
PharmaVOICE - The RWE Evolution
Apr 13, 2021
Article
How RWE can help Biotechs optimize the value of their asset
Apr 5, 2021
Whitepaper
Getting real-world data into clinical research
Aug 26, 2020
Podcast
The opportunity for biotechs in precision medicine
Mar 5, 2020
related insights
Webinar
Leveraging post-marketing regulatory requirements to drive commercial value
Oct 16, 2024
Blog
Transforming evidence generation: How predictive AI can optimize clinical development
Sep 3, 2024
Whitepaper
Combining data tokenization and real-world patient insights to bridge the gap for a more diverse and complete dataset
Apr 2, 2024
Blog
Deriving meaningful insights from real-world data for diverse Alzheimer’s research studies
Mar 19, 2024
Blog
Removing barriers through pragmatic clinical trials
Oct 12, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Webinar
Adaptive strategies for more efficient, data-rich and patient-friendly trials
May 28, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
Guide for Real-World Evidence
May 21, 2021
Article
PharmaVOICE - The RWE Evolution
Apr 13, 2021
Article
How RWE can help Biotechs optimize the value of their asset
Apr 5, 2021
Whitepaper
Getting real-world data into clinical research
Aug 26, 2020
Podcast
The opportunity for biotechs in precision medicine
Mar 5, 2020
Frost & Sullivan's 2023 North American Customer Value Leadership Award
Parexel Recognized with Frost & Sullivan's 2023 North American Customer Value Leadership Award for impactful real-world evidence solutions addressing customer needs.
FREQUENTLY ASKED QUESTIONS
RWE describes clinical evidence about the usage and potential benefits or risks of a medical product or practice. RWE is derived from the transformation, analysis, and interpretation of real-world data (RWD) for use in clinical, policy, payer, or other decisions.
RWE drives the differentiation of value against standard of care, comparable products on the market and new entrants.
Early in the clinical trial planning process, RWE helps identify the appropriate patient populations, and utilizes RWD sources to support inclusion/exclusion criteria.
RWE empowers innovative trials. By combining site-based data with electronic health records and registry data, phase II/III hybrid trials can be conducted. RWE also enhances data from single-arm trials by utilizing external/historic controls. Furthermore, it allows for the creation of external control arms to validate more rigorous comparison to patients in active treatment arms.
RWE is useful for drug approval because it allows for informed decision making at the right time and assists companies in meeting the expectations of regulators. By utilizing RWD, it enhances the pathway to regulatory approval, from integrated product development planning, through health authority engagement to regulatory submission. And it demonstrates value through evidence-based health economic evaluation and outcomes research.